{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T15:07:27Z","timestamp":1778684847322,"version":"3.51.4"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100013252","name":"TG Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013252","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s40120-026-00904-4","type":"journal-article","created":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T01:47:33Z","timestamp":1772761653000},"page":"1081-1097","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy of Ublituximab in People with Highly Active Relapsing Multiple Sclerosis"],"prefix":"10.1007","volume":"15","clinical-trial-number":[{"clinical-trial-number":"nct03277261","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03277248","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Hans-Peter","family":"Hartung","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Derrick","family":"Robertson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lawrence","family":"Steinman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas L.","family":"Arnold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peiqing","family":"Qian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sibyl","family":"Wray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward","family":"Fox","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher A.","family":"Garner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yihuan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koby","family":"Mok","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Gocke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce A. C.","family":"Cree","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrique","family":"Alvarez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,6]]},"reference":[{"key":"904_CR1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2015.00322","volume":"6","author":"C Riedhammer","year":"2015","unstructured":"Riedhammer C, Weissert R. Antigen presentation, autoantigens, and immune regulation in multiple sclerosis and other autoimmune diseases. Front Immunol. 2015;6:322. https:\/\/doi.org\/10.3389\/fimmu.2015.00322.","journal-title":"Front Immunol"},{"key":"904_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1129906","volume":"14","author":"MJ Furman","year":"2023","unstructured":"Furman MJ, Meuth SG, Albrecht P, et al. B\u00a0cell targeted therapies in inflammatory autoimmune disease of the central nervous system. Front Immunol. 2023;14:1129906. https:\/\/doi.org\/10.3389\/fimmu.2023.1129906.","journal-title":"Front Immunol"},{"issue":"1","key":"904_CR3","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/ene.13819","volume":"26","author":"R Dobson","year":"2019","unstructured":"Dobson R, Giovannoni G. Multiple sclerosis - a review. Eur J Neurol. 2019;26(1):27\u201340. https:\/\/doi.org\/10.1111\/ene.13819.","journal-title":"Eur J Neurol"},{"issue":"3","key":"904_CR4","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s40265-024-02011-w","volume":"84","author":"AK Carlson","year":"2024","unstructured":"Carlson AK, Amin M, Cohen JA. Drugs targeting CD20 in multiple sclerosis: pharmacology, efficacy, safety, and tolerability. Drugs. 2024;84(3):285\u2013304. https:\/\/doi.org\/10.1007\/s40265-024-02011-w.","journal-title":"Drugs"},{"issue":"1","key":"904_CR5","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1002\/ana.25927","volume":"89","author":"G Comi","year":"2021","unstructured":"Comi G, Bar-Or A, Lassmann H, et al. Role of B\u00a0cells in multiple sclerosis and related disorders. Ann Neurol. 2021;89(1):13\u201323. https:\/\/doi.org\/10.1002\/ana.25927.","journal-title":"Ann Neurol"},{"issue":"1","key":"904_CR6","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1002\/ana.25119","volume":"83","author":"AL Greenfield","year":"2018","unstructured":"Greenfield AL, Hauser SL. B-cell therapy for multiple sclerosis: entering an era. Ann Neurol. 2018;83(1):13\u201326. https:\/\/doi.org\/10.1002\/ana.25119.","journal-title":"Ann Neurol"},{"issue":"2","key":"904_CR7","doi-asserted-by":"publisher","first-page":"580","DOI":"10.4049\/jimmunol.1400118","volume":"193","author":"A Palanichamy","year":"2014","unstructured":"Palanichamy A, Jahn S, Nickles D, et al. Rituximab efficiently depletes increased CD20-expressing T\u00a0cells in multiple sclerosis patients. J Immunol. 2014;193(2):580\u20136. https:\/\/doi.org\/10.4049\/jimmunol.1400118.","journal-title":"J Immunol"},{"issue":"3","key":"904_CR8","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2207291120","volume":"120","author":"K Shinoda","year":"2023","unstructured":"Shinoda K, Li R, Rezk A, et al. Differential effects of anti-CD20 therapy on CD4 and CD8 T\u00a0cells and implication of CD20-expressing CD8 T\u00a0cells in MS disease activity. Proc Natl Acad Sci U S A. 2023;120(3):e2207291120. https:\/\/doi.org\/10.1073\/pnas.2207291120.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"904_CR9","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200004","volume":"9","author":"MR von Essen","year":"2022","unstructured":"von Essen MR, Hansen RH, Hojgaard C, Ammitzboll C, Wiendl H, Sellebjerg F. Ofatumumab modulates inflammatory T\u00a0cell responses and migratory potential in patients with multiple sclerosis. Neurol Neuroimmunol Neuroinflamm. 2022;9(4):e200004. https:\/\/doi.org\/10.1212\/NXI.0000000000200004.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"6","key":"904_CR10","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1007\/s40263-025-01182-8","volume":"39","author":"BAC Cree","year":"2025","unstructured":"Cree BAC, Berger JR, Greenberg B. The evolution of anti-CD20 treatment for multiple sclerosis: optimization of antibody characteristics and function. CNS Drugs. 2025;39(6):545\u201364. https:\/\/doi.org\/10.1007\/s40263-025-01182-8.","journal-title":"CNS Drugs"},{"issue":"4","key":"904_CR11","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1080\/13543784.2018.1459560","volume":"27","author":"HM Babiker","year":"2018","unstructured":"Babiker HM, Glode AE, Cooke LS, Mahadevan D. Ublituximab for the treatment of CD20 positive B-cell malignancies. Expert Opin Investig Drugs. 2018;27(4):407\u201312. https:\/\/doi.org\/10.1080\/13543784.2018.1459560.","journal-title":"Expert Opin Investig Drugs"},{"issue":"3","key":"904_CR12","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1177\/1352458520918375","volume":"27","author":"E Fox","year":"2021","unstructured":"Fox E, Lovett-Racke AE, Gormley M, et al. A phase\u00a02 multicenter study of ublituximab, a novel glycoengineered anti-CD20 monoclonal antibody, in patients with relapsing forms of multiple sclerosis. Mult Scler. 2021;27(3):420\u20139. https:\/\/doi.org\/10.1177\/1352458520918375.","journal-title":"Mult Scler"},{"issue":"1","key":"904_CR13","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/leu.2010.240","volume":"25","author":"M Le Garff-Tavernier","year":"2011","unstructured":"Le Garff-Tavernier M, Decocq J, de Romeuf C, et al. Analysis of CD16+CD56dim NK cells from CLL patients: evidence supporting a therapeutic strategy with optimized anti-CD20 monoclonal antibodies. Leukemia. 2011;25(1):101\u20139. https:\/\/doi.org\/10.1038\/leu.2010.240.","journal-title":"Leukemia"},{"key":"904_CR14","unstructured":"BRIUMVI (ublituximab-xiiy). Prescribing information. TG Therapeutics; 2022. https:\/\/www.tgtherapeutics.com\/label-prescribing-info\/uspi-briumvi.pdf. Accessed 1 Oct 2024."},{"key":"904_CR15","unstructured":"Alvarez A, Steinman L, Fox EJ, et al. Reduced disease progression with ublituximab vs teriflunomide in the phase 3 ULTIMATE I and II studies in relapsing multiple sclerosis. In: Consortium of Multiple Sclerosis Centers; June 1\u20134 2022; National Harbor, MD."},{"issue":"8","key":"904_CR16","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1056\/NEJMoa2201904","volume":"387","author":"L Steinman","year":"2022","unstructured":"Steinman L, Fox E, Hartung HP, et al. Ublituximab versus teriflunomide in relapsing multiple sclerosis. N Engl J Med. 2022;387(8):704\u201314. https:\/\/doi.org\/10.1056\/NEJMoa2201904.","journal-title":"N Engl J Med"},{"key":"904_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2024.1473284","volume":"15","author":"E Alvarez","year":"2024","unstructured":"Alvarez E, Steinman L, Fox EJ, et al. Improvements in no evidence of disease activity with ublituximab vs. teriflunomide in the ULTIMATE phase\u00a03 studies in relapsing multiple sclerosis. Front Neurol. 2024;15:1473284. https:\/\/doi.org\/10.3389\/fneur.2024.1473284.","journal-title":"Front Neurol"},{"key":"904_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1132170","volume":"14","author":"J Correale","year":"2023","unstructured":"Correale J, Rush CA, Barboza A. Are highly active and aggressive multiple sclerosis the same entity? Front Neurol. 2023;14:1132170. https:\/\/doi.org\/10.3389\/fneur.2023.1132170.","journal-title":"Front Neurol"},{"key":"904_CR19","doi-asserted-by":"publisher","DOI":"10.1177\/1756286420935019","volume":"13","author":"PS S\u00f8rensen","year":"2020","unstructured":"S\u00f8rensen PS, Centonze D, Giovannoni G, et al. Expert opinion on the use of cladribine tablets in clinical practice. Ther Adv Neurol Disord. 2020;13:1756286420935019. https:\/\/doi.org\/10.1177\/1756286420935019.","journal-title":"Ther Adv Neurol Disord"},{"key":"904_CR20","doi-asserted-by":"publisher","DOI":"10.1177\/17562864211039648","volume":"14","author":"H Wiendl","year":"2021","unstructured":"Wiendl H, Gold R, Berger T, et al. Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper). Ther Adv Neurol Disord. 2021;14:17562864211039648. https:\/\/doi.org\/10.1177\/17562864211039648.","journal-title":"Ther Adv Neurol Disord"},{"issue":"9","key":"904_CR21","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1177\/1352458520924595","volume":"26","author":"G Arrambide","year":"2020","unstructured":"Arrambide G, Iacobaeus E, Amato MP, et al. Aggressive multiple sclerosis (2): treatment. Mult Scler. 2020;26(9):1045\u201363. https:\/\/doi.org\/10.1177\/1352458520924595.","journal-title":"Mult Scler"},{"key":"904_CR22","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.msard.2017.07.003","volume":"17","author":"\u00d3 Fern\u00e1ndez","year":"2017","unstructured":"Fern\u00e1ndez \u00d3. Is there a change of paradigm towards more effective treatment early in the course of apparent high-risk MS? Mult Scler Relat Disord. 2017;17:75\u201383. https:\/\/doi.org\/10.1016\/j.msard.2017.07.003.","journal-title":"Mult Scler Relat Disord"},{"key":"904_CR23","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.70131","author":"P Iaffaldano","year":"2025","unstructured":"Iaffaldano P, Lucisano G, Guerra T, et al. Early intensive versus escalation approach: ten-year impact on disability in relapsing multiple sclerosis. Ann Clin Transl Neurol. 2025. https:\/\/doi.org\/10.1002\/acn3.70131.","journal-title":"Ann Clin Transl Neurol"},{"issue":"7","key":"904_CR24","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/nrneurol.2015.85","volume":"11","author":"CA Rush","year":"2015","unstructured":"Rush CA, MacLean HJ, Freedman MS. Aggressive multiple sclerosis: proposed definition and treatment algorithm. Nat Rev Neurol. 2015;11(7):379\u201389. https:\/\/doi.org\/10.1038\/nrneurol.2015.85.","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"904_CR25","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s00415-023-11969-8","volume":"271","author":"K Selmaj","year":"2024","unstructured":"Selmaj K, Cree BAC, Barnett M, Thompson A, Hartung HP. Multiple sclerosis: time for early treatment with high-efficacy drugs. J Neurol. 2024;271(1):105\u201315. https:\/\/doi.org\/10.1007\/s00415-023-11969-8.","journal-title":"J Neurol"},{"issue":"1","key":"904_CR26","doi-asserted-by":"publisher","DOI":"10.1177\/20552173231154712","volume":"9","author":"R Alonso","year":"2023","unstructured":"Alonso R, Casas M, Lazaro L, et al. Achieving no evidence of disease activity-3 in highly active multiple sclerosis patients treated with cladribine and monoclonal antibodies. Mult Scler J Exp Transl Clin. 2023;9(1):20552173231154712. https:\/\/doi.org\/10.1177\/20552173231154712.","journal-title":"Mult Scler J Exp Transl Clin"},{"issue":"4","key":"904_CR27","doi-asserted-by":"publisher","first-page":"2579","DOI":"10.1007\/s13311-021-01104-8","volume":"18","author":"M Cellerino","year":"2021","unstructured":"Cellerino M, Boffa G, Lapucci C, et al. Predictors of ocrelizumab effectiveness in patients with multiple sclerosis. Neurotherapeutics. 2021;18(4):2579\u201388. https:\/\/doi.org\/10.1007\/s13311-021-01104-8.","journal-title":"Neurotherapeutics"},{"key":"904_CR28","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.msard.2019.01.039","volume":"30","author":"C D\u00edaz","year":"2019","unstructured":"D\u00edaz C, Zarco LA, Rivera DM. Highly active multiple sclerosis: an update. Mult Scler Relat Disord. 2019;30:215\u201324. https:\/\/doi.org\/10.1016\/j.msard.2019.01.039.","journal-title":"Mult Scler Relat Disord"},{"issue":"11","key":"904_CR29","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awaa306","volume":"143","author":"D Ellenberger","year":"2020","unstructured":"Ellenberger D, Flachenecker P, Fneish F, et al. Aggressive multiple sclerosis: a matter of measurement and timing. Brain. 2020;143(11):e97. https:\/\/doi.org\/10.1093\/brain\/awaa306.","journal-title":"Brain"},{"issue":"9","key":"904_CR30","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1007\/s40263-020-00749-x","volume":"34","author":"T Ziemssen","year":"2020","unstructured":"Ziemssen T, Bass AD, Berkovich R, et al. Efficacy and safety of alemtuzumab through 9\u00a0years of follow-up in patients with highly active disease: post hoc analysis of CARE-MS I and II patients in the TOPAZ extension study. CNS Drugs. 2020;34(9):973\u201388. https:\/\/doi.org\/10.1007\/s40263-020-00749-x.","journal-title":"CNS Drugs"},{"issue":"7","key":"904_CR31","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1093\/brain\/awq118","volume":"133","author":"A Scalfari","year":"2010","unstructured":"Scalfari A, Neuhaus A, Degenhardt A, et al. The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability. Brain. 2010;133(7):1914\u201329. https:\/\/doi.org\/10.1093\/brain\/awq118.","journal-title":"Brain"},{"key":"904_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2023.104861","volume":"77","author":"H Ahvenj\u00e4rvi","year":"2023","unstructured":"Ahvenj\u00e4rvi H, Niiranen M, Simula S, et al. Fatigue and health-related quality of life depend on the disability status and clinical course in RRMS. Mult Scler Relat Disord. 2023;77:104861. https:\/\/doi.org\/10.1016\/j.msard.2023.104861.","journal-title":"Mult Scler Relat Disord"},{"issue":"9","key":"904_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2017.08.1975","volume":"20","author":"T Spelman","year":"2017","unstructured":"Spelman T, Geale K, Anell B, Hillert J, Wong SL. The association between disease activity and health-related quality of life in RRMS patients. Value Health. 2017;20(9):A728. https:\/\/doi.org\/10.1016\/j.jval.2017.08.1975.","journal-title":"Value Health"},{"issue":"6","key":"904_CR34","doi-asserted-by":"publisher","first-page":"3142","DOI":"10.1007\/s00415-024-12256-w","volume":"271","author":"M Guger","year":"2024","unstructured":"Guger M, Enzinger C, Leutmezer F, et al. Early intensive versus escalation treatment in patients with relapsing-remitting multiple sclerosis in Austria. J Neurol. 2024;271(6):3142\u201352. https:\/\/doi.org\/10.1007\/s00415-024-12256-w.","journal-title":"J Neurol"},{"issue":"1","key":"904_CR35","doi-asserted-by":"publisher","first-page":"84","DOI":"10.5603\/pjnns.97040","volume":"58","author":"M Popiel","year":"2024","unstructured":"Popiel M, Bartosik-Psujek H. Clinical and radiological consequences of delayed therapy escalation in patients with relapsing-remitting multiple sclerosis. Neurol Neurochir Pol. 2024;58(1):84\u201393. https:\/\/doi.org\/10.5603\/pjnns.97040.","journal-title":"Neurol Neurochir Pol"},{"key":"904_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.693017","volume":"12","author":"CS Simonsen","year":"2021","unstructured":"Simonsen CS, Flemmen H, Broch L, et al. Early high efficacy treatment in multiple sclerosis is the best predictor of future disease activity over 1 and 2\u00a0years in a Norwegian population-based registry. Front Neurol. 2021;12:693017. https:\/\/doi.org\/10.3389\/fneur.2021.693017.","journal-title":"Front Neurol"},{"issue":"10","key":"904_CR37","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1001\/jamaneurol.2021.2738","volume":"78","author":"T Spelman","year":"2021","unstructured":"Spelman T, Magyari M, Piehl F, et al. Treatment escalation vs immediate initiation of highly effective treatment for patients with relapsing-remitting multiple sclerosis: data from 2 different national strategies. JAMA Neurol. 2021;78(10):1197\u2013204. https:\/\/doi.org\/10.1001\/jamaneurol.2021.2738.","journal-title":"JAMA Neurol"},{"issue":"2","key":"904_CR38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0016664","volume":"6","author":"T Castillo-Trivino","year":"2011","unstructured":"Castillo-Trivino T, Mowry EM, Gajofatto A, et al. Switching multiple sclerosis patients with breakthrough disease to second-line therapy. PLoS ONE. 2011;6(2):e16664. https:\/\/doi.org\/10.1371\/journal.pone.0016664.","journal-title":"PLoS ONE"},{"key":"904_CR39","doi-asserted-by":"publisher","DOI":"10.1212\/nxi.0000000000001059","author":"L Prosperini","year":"2021","unstructured":"Prosperini L, Ruggieri S, Haggiag S, Tortorella C, Pozzilli C, Gasperini C. Prognostic accuracy of NEDA-3 in long-term outcomes of multiple sclerosis. Neurol Neuroimmunol Neuroinflamm. 2021. https:\/\/doi.org\/10.1212\/nxi.0000000000001059.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"2","key":"904_CR40","doi-asserted-by":"publisher","first-page":"e209","DOI":"10.1212\/wnl.0000000000200549","volume":"99","author":"D Rotstein","year":"2022","unstructured":"Rotstein D, Solomon JM, Sormani MP, et al. Association of no evidence of disease activity with no long-term disability progression in multiple sclerosis: a systematic review and meta-analysis. Neurology. 2022;99(2):e209\u201320. https:\/\/doi.org\/10.1212\/wnl.0000000000200549.","journal-title":"Neurology"},{"key":"904_CR41","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.1034056","volume":"13","author":"CS Simonsen","year":"2022","unstructured":"Simonsen CS, Flemmen H, Broch L, et al. Rebaseline no evidence of disease activity (NEDA-3) as a predictor of long-term disease course in a Norwegian multiple sclerosis population. Front Neurol. 2022;13:1034056. https:\/\/doi.org\/10.3389\/fneur.2022.1034056.","journal-title":"Front Neurol"},{"issue":"6","key":"904_CR42","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1056\/NEJMoa1917246","volume":"383","author":"SL Hauser","year":"2020","unstructured":"Hauser SL, Bar-Or A, Cohen JA, et al. Ofatumumab versus teriflunomide in multiple sclerosis. N Engl J Med. 2020;383(6):546\u201357. https:\/\/doi.org\/10.1056\/NEJMoa1917246.","journal-title":"N Engl J Med"},{"issue":"3","key":"904_CR43","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa1601277","volume":"376","author":"SL Hauser","year":"2017","unstructured":"Hauser SL, Bar-Or A, Comi G, et al. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med. 2017;376(3):221\u201334. https:\/\/doi.org\/10.1056\/NEJMoa1601277.","journal-title":"N Engl J Med"},{"issue":"3","key":"904_CR44","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1007\/s00415-021-10744-x","volume":"269","author":"M Margoni","year":"2022","unstructured":"Margoni M, Preziosa P, Filippi M, Rocca MA. Anti-CD20 therapies for multiple sclerosis: current status and future perspectives. J Neurol. 2022;269(3):1316\u201334. https:\/\/doi.org\/10.1007\/s00415-021-10744-x.","journal-title":"J Neurol"},{"issue":"17","key":"904_CR45","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1212\/wnl.0000000000005347","volume":"90","author":"A Rae-Grant","year":"2018","unstructured":"Rae-Grant A, Day GS, Marrie RA, et al. Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2018;90(17):777\u201388. https:\/\/doi.org\/10.1212\/wnl.0000000000005347.","journal-title":"Neurology"},{"issue":"2","key":"904_CR46","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1177\/1352458517751049","volume":"24","author":"X Montalban","year":"2018","unstructured":"Montalban X, Gold R, Thompson AJ, et al. ECTRIMS\/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. Mult Scler. 2018;24(2):96\u2013120. https:\/\/doi.org\/10.1177\/1352458517751049.","journal-title":"Mult Scler"},{"issue":"9","key":"904_CR47","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1185\/03007995.2015.1067191","volume":"31","author":"T Derfuss","year":"2015","unstructured":"Derfuss T, Bergvall NK, Sfikas N, Tomic DL. Efficacy of fingolimod in patients with highly active relapsing-remitting multiple sclerosis. Curr Med Res Opin. 2015;31(9):1687\u201391. https:\/\/doi.org\/10.1185\/03007995.2015.1067191.","journal-title":"Curr Med Res Opin"},{"issue":"5","key":"904_CR48","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1007\/s00415-019-09248-6","volume":"266","author":"B Turner","year":"2019","unstructured":"Turner B, Cree BAC, Kappos L, et al. Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis. J Neurol. 2019;266(5):1182\u201393. https:\/\/doi.org\/10.1007\/s00415-019-09248-6.","journal-title":"J Neurol"},{"issue":"12","key":"904_CR49","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000210049","volume":"103","author":"HP Hartung","year":"2024","unstructured":"Hartung HP, Benedict RHB, Berger T, et al. Ocrelizumab in early-stage relapsing-remitting multiple sclerosis: the phase\u00a0IIIb ENSEMBLE 4-year, single-arm, open-label trial. Neurology. 2024;103(12):e210049. https:\/\/doi.org\/10.1212\/wnl.0000000000210049.","journal-title":"Neurology"},{"issue":"2","key":"904_CR50","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1007\/s13311-022-01202-1","volume":"19","author":"F Rollot","year":"2022","unstructured":"Rollot F, Couturier J, Casey R, et al. Comparative effectiveness of natalizumab versus anti-CD20 in highly active relapsing-remitting multiple sclerosis after fingolimod withdrawal. Neurotherapeutics. 2022;19(2):476\u201390. https:\/\/doi.org\/10.1007\/s13311-022-01202-1.","journal-title":"Neurotherapeutics"},{"key":"904_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2024.105594","volume":"87","author":"E Signoriello","year":"2024","unstructured":"Signoriello E, Signori A, Lus G, et al. NEDA-3 achievement in early highly active relapsing remitting multiple sclerosis patients treated with ocrelizumab or natalizumab. Mult Scler Relat Disord. 2024;87:105594. https:\/\/doi.org\/10.1016\/j.msard.2024.105594.","journal-title":"Mult Scler Relat Disord"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-00904-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-026-00904-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-00904-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T14:08:11Z","timestamp":1778681291000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-026-00904-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,6]]},"references-count":51,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["904"],"URL":"https:\/\/doi.org\/10.1007\/s40120-026-00904-4","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,6]]},"assertion":[{"value":"16 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Enrique Alvarez has received compensation for advisory boards, lectures, and consultancy with Biogen, Celgene\/BMS, Cionic, EMD Serono\/Merck, Genentech\/Roche, Genzyme, Horizon\/Amgen, Novartis, Sanofi, and TG Therapeutics, and research support from Biogen, Genentech\/Roche, Novartis, TG Therapeutics, Patient-Centered Outcomes Research Institute, National Multiple Sclerosis Society, National Institutes of Health, and Rocky Mountain MS Center. Hans-Peter Hartung has received honoraria for serving on steering and data monitoring committees, consulting, and speaking at symposia from Aurinia Pharma, Bayer Pharma AG, Biogen Idec, BMS Celgene, Merck KG Darmstadt, Neuraxpharm, Novartis, Roche, Sanofi, and TG Therapeutics, with approval by the rector of Heinrich-Heine University. Hans-Peter Hartung is an Editorial Board member of\n                      Neurology and Therapy\n                      . Hans-Peter Hartung was not involved in the selection of peer reviewers nor any of the subsequent editorial decisions. Lawrence Steinman has received research support and honoraria from BMS, Roche, and TG Therapeutics. Dr. Steinman serves on the Board of BioAtla and Pasithea Therapeutics. Derrick Robertson has received grant support from Anokion, Atara Biotherapeutics, Biogen, CorEvitas, EMD Serono, Genentech, GW Pharmaceuticals, Janssen, Novartis, PCORI, PRIME CME, Sanofi, TG Therapeutics, and UCB; has received consulting fees from Alexion, Amgen, Biogen, Bristol Myers Squibb, EMD Serono, Genentech, Greenwich Biosciences, Horizon, ImmPACT Bio, Janssen, Mallinckrodt, Novartis, Sanofi, and TG Therapeutics; has received honoraria or speaker fees from Alexion, Amgen, Biogen, Bristol Myers Squibb, EMD Serono, Genentech, Horizon, Janssen, PRIME CME, Sanofi, and TG Therapeutics. Peiqing Qian has received speaking and consulting honoraria from Biogen, BMS, Genzyme, Genentech, Viela Bio, and TG Therapeutics. Sibyl Wray has received compensation for serving on a scientific advisory or data safety monitoring board for Biogen, Bristol Myers Squibb\/Celgene, EMD Serono, Novartis, Roche\/Genentech, and Sanofi\/Genzyme, and has received compensation for serving on a speaker\u2019s bureau for Biogen, Bristol Myers Squibb, EMD Serono, Roche\/Genentech, and Sanofi\/Genzyme. The institution of Dr. Wray has received research support from Amgen, Biogen, Bristol Myers Squibb\/Celgene, Contineum, Novartis, Roche\/Genentech, Sanofi\/Genzyme, and TG Therapeutics. Douglas L. Arnold has received consulting fees from Biogen, Celgene, Eli Lilly, EMD Serono, Frequency Therapeutics, Merck, Novartis, Roche, Sanofi, and Xfacto and holds stock in NeuroRx. Edward Fox, Yihuan Xu, Koby Mok, Anne Gocke, and Christopher Garner are all employees of TG Therapeutics, Inc. Bruce Cree is a consultant for Alexion, Alumis, Avotres, Biogen, Boston Pharma, EMD Serono, Hexal\/Sandoz, Horizon, Immunic AG, Kyverna, Neuron23, Novartis, Sanofi, Siemens, and TG Therapeutics, received research support from Genentech and Kyverna, and is on an advisory board for Autobahn.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Each study site's institutional review board or ethics committee approved the trials (US central IRB approval reference numbers ULTIMATE\u00a0I Pro00021474, ULTIMATE\u00a0II Pro00021820), which adhered to Good Clinical Practice guidelines and the principles of the Declaration of Helsinki. Written informed consent was obtained from all participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}